RecruitingNot ApplicableNCT06084195

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle

Enrollment

120 participants

Start Date

Dec 19, 2023

Study Type

INTERVENTIONAL

Conditions

High Grade Serous Ovarian Cancer

Summary

The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced imaging (including special MRI and PET scans) to better understand the biology of ovarian cancer tumors. The goal is to find imaging features that reflect how the tumor behaves biologically, which could one day guide more personalized treatment decisions. **You may be eligible if...** - You are older than 18 - You have been confirmed or suspected to have advanced high-grade serous ovarian cancer (stage IIIB or IIIC or higher) - You are scheduled for surgery, with or without prior chemotherapy - You are enrolled in the French health insurance system - You have given written consent **You may NOT be eligible if...** - Your cancer is early stage or has already spread beyond the abdomen - You will not be having surgery - You have had another cancer in the past 5 to 10 years - You are under guardianship or unable to consent - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBlood sample and tissue sample

During the surgery : * Tissus sample : primary tumor and metastasis * blood sample : 3 EDTA tubes * ex vivo MRI data

Locations(1)

NOUGARET Stephanie

Montpellier, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06084195

Related Trials

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT0557936666 locations

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540345 locations

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

NCT050278281 location

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NCT075038085 locations

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT0528147131 locations